

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

CD34 Monoclonal Antibody (4H11), FITC, eBioscience

RRID:AB_1518732

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 11-0349-42, RRID:AB_1518732)

Antibody Information

URL: http://antibodyregistry.org/AB_1518732

Proper Citation: (Thermo Fisher Scientific Cat# 11-0349-42, RRID:AB_1518732)

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow
Consolidation on 1/2020: AB_1518732, AB_10412940

Antibody Name: CD34 Monoclonal Antibody (4H11), FITC, eBioscience

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: Clone 4H11

Antibody ID: AB_1518732

Vendor: Thermo Fisher Scientific

Catalog Number: 11-0349-42

Record Creation Time: 20251213T073523+0000

Record Last Update: 20260225T230651+0000

Ratings and Alerts

No rating or validation information has been found for CD34 Monoclonal Antibody (4H11), FITC, eBioscience.

No alerts have been found for CD34 Monoclonal Antibody (4H11), FITC, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Neehus AL, et al. (2024) Human inherited CCR2 deficiency underlies progressive polycystic lung disease. *Cell*, 187(2), 390.

Han L, et al. (2023) METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. *Cell stem cell*, 30(1), 52.

Liu C, et al. (2022) Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. *Cell metabolism*, 34(6), 818.

Qing Y, et al. (2021) Evaluation of glycolytic rates in human hematopoietic stem/progenitor cells after target gene depletion. *STAR protocols*, 2(2), 100603.

Zhou XB, et al. (2020) Generation and characterization of two iPSC lines from human adipose tissue-derived stem cells of healthy donors. *Stem cell research*, 48, 101973.

Su R, et al. (2020) Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. *Cancer cell*, 38(1), 79.